)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
SIGA Technologies
SIGA Technologies (SIGA) investor relations material
SIGA Technologies Company presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Company presentation summary7 Aug, 2026
Company overview and strategic priorities
Focuses on infectious diseases and global health security, with a primary emphasis on smallpox treatment and prevention.
Operates as a fully integrated, commercial-stage pharmaceutical company with expertise in government contracting.
Strategic priorities include expanding regulatory approvals, global partnerships, and moving into complementary therapeutic areas.
Maintains a robust balance sheet with disciplined cash management and no debt.
Product platform and differentiation
TPOXX (tecovirimat) is a highly targeted antiviral approved in the US, Canada, EU, UK, and Japan for smallpox treatment.
Demonstrates strong efficacy and safety in both preclinical and clinical studies, with no serious adverse events reported.
One of only two approved antivirals for orthopoxvirus treatment, with a differentiated mechanism targeting the VP37 protein.
TPOXX is positioned as a foundational franchise with a track record of multi-year government contracts.
Market need and threat landscape
Smallpox remains a significant global threat due to increased vulnerability, synthetic biology advances, and geopolitical risks.
Vaccines alone are insufficient; comprehensive preparedness requires both vaccines and antivirals.
Most of the current population is unvaccinated, increasing susceptibility to outbreaks.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from SIGA Technologies
- Q2 2026 revenues and net income fell, offset by international sales and a special dividend.SIGA
Q2 2026 - All proposals passed, with strong financials and strategic TPOXX initiatives highlighted.SIGAAGM 2026
- Shareholders to vote on expanding the equity plan by 6.5 million shares for talent retention.SIGAProxy filing
- TPOXX drives global health security leadership, robust growth, and strong government partnerships.SIGACorporate presentation
- Q1 2026 saw lower revenue, a net loss, special dividend, and global expansion plans.SIGAQ1 2026
- Annual meeting covers director elections, auditor ratification, and stock plan amendment.SIGAProxy filing
- Stockholders will vote on director elections, auditor ratification, executive pay, and a major equity plan increase.SIGAProxy filing
- TPOXX antiviral franchise and strong government contracts drive robust growth and financials.SIGACompany presentation
- Nine-month revenues hit $57.3M, fueled by $122M in U.S. orders and a $0.60 dividend paid.SIGAQ3 2024
Next SIGA Technologies earnings date
Q3 20269 Nov, 2026
SIGA Technologies
Next SIGA Technologies earnings date
Q3 20269 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
SIGA Technologies, Inc. is a pharmaceutical company focused on the development and commercialization of countermeasures to address infectious diseases and biological threats. The company specializes in antiviral therapies, with a particular emphasis on treatments for diseases caused by orthopoxviruses, including smallpox. SIGA’s products are primarily used by government agencies and health organizations to strengthen preparedness for potential outbreaks or bioterrorism events. The company is headquartered in New York, New York, and its shares are listed on the NASDAQ.